288 related articles for article (PubMed ID: 36845706)
1. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
[TBL] [Abstract][Full Text] [Related]
3. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.
Liu Z; Gao Z; Zhang M; Wang X; Gong J; Jiang S; Zhang Z
Ann Thorac Cardiovasc Surg; 2022 Apr; 28(2):111-120. PubMed ID: 34776459
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
[TBL] [Abstract][Full Text] [Related]
6. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
7. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
8. Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
Du C; Chen Y; Zhou Y; Zheng D; Zhao J; Tang J; Wu Y; Tu Z
BMC Cancer; 2023 Dec; 23(1):1260. PubMed ID: 38129808
[TBL] [Abstract][Full Text] [Related]
9. Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP).
Faehling M; Witte H; Sebastian M; Ulmer M; Sätzler R; Steinestel K; Brückl WM; Evers G; Büschenfelde CMZ; Bleckmann A
Ther Adv Med Oncol; 2022; 14():17588359221085333. PubMed ID: 35356258
[TBL] [Abstract][Full Text] [Related]
10. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z
Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509
[TBL] [Abstract][Full Text] [Related]
11. Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer.
Tao Y; Li X; Liu B; Wang J; Lv C; Li S; Wang Y; Chen J; Yan S; Wu N
Front Oncol; 2023; 13():1135140. PubMed ID: 37256186
[TBL] [Abstract][Full Text] [Related]
12. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
[TBL] [Abstract][Full Text] [Related]
13. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
15. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
17. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
18. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
[TBL] [Abstract][Full Text] [Related]
19. Utility of
Chen X; Bai G; Zang R; Song P; Bie F; Huai Q; Li Y; Liu Y; Zhou B; Bie Y; Yang Z; Gao S
Transl Oncol; 2023 Sep; 35():101725. PubMed ID: 37421908
[TBL] [Abstract][Full Text] [Related]
20. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.
Wang S; Sun X; Dong J; Liu L; Zhao H; Li R; Yang Z; Cheng N; Wang Y; Fu L; Yi H; Lv Z; Huo H; Jin D; Mao Y; Yang L
Cell Oncol (Dordr); 2024 Feb; ():. PubMed ID: 38319500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
